1. Prolonged and tunable residence time using reversible covalent kinase inhibitors;Bradshaw;Nat Chem Biol,2015
2. Pemphigus vulgaris: present and future therapeutic strategies;Didona;Dermatol Pract Concept,2022
3. Open trial of bruton’s tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus;Goodale;Vet Dermatol,2020
4. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial;Joly;Lancet,2017
5. Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia;Kuter;N Engl J Med,2022